Fidelis Ayebae's Fidson Healthcare wrapped up a massive rights offering in early 2026. Investors snapped up N24.65 billion worth of shares against just N21 billion on offer.
That 117 percent oversubscription sent a powerful signal about market confidence. Three decades of pharmaceutical work had earned the company genuine credibility.
But success comes with a cost. Shareholders who didn't participate in the rights issue faced immediate dilution of their stakes.
Fidson's first-quarter 2026 results painted an encouraging operational picture regardless. Revenue climbed 22 percent during the period, signaling solid business performance.
Yet the founder's paper loss underscores a hard truth in capital markets. Even celebrated businesses must contend with ownership stakes that shrink over time.
